Trial
NCT00687596
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Taiho Oncology, Inc.
Collaborators
Quintiles, Inc.
Condition
Hepatocellular Carcinoma
Intervention
TAC-101
Why stopped
Terminated due to safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19